DBV Technologies | Spese Di Vendita E Di Amministrazione



Selling And Administration Expenses Cambiamento Data
Acadia Pharmaceuticals USD 130.08M 3.21M 2024-12
Alnylam Pharmaceuticals USD 295.34M 74.35M 2024-12
Amarin USD 36.9M 1.64M 2024-09
BioMarin Pharmaceutical USD 256.77M 46.81M 2024-12
DBV Technologies USD 6.24M 1.32M 2024-09
Halozyme Therapeutics USD 42.25M 1.01M 2024-12
Incyte USD 326.71M 17.5M 2024-12
Insmed USD 142.51M 23.58M 2024-12
Ionis Pharmaceuticals USD 88.08M 26.44M 2024-12
Neurocrine Biosciences USD 287.8M 53.5M 2024-12
PTC Therapeutics USD 84.68M 11.23M 2024-12
Sarepta Therapeutics USD 163.87M 35.67M 2024-12
Ultragenyx Pharmaceutical USD 82.49M 2.14M 2024-12
United Therapeutics USD 162.5M 8.4M 2024-12



DBV Technologies Spese Di Vendita E Di Amministrazione - Valori correnti, dati storici, previsioni, statistiche, grafici e calendario economico - Apr 2025.